Teva Pharmaceutical Industries Ltd (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: May 18, 2017
Pages: 249
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T3E12D7D2CAEN
Leaflet:

Download PDF Leaflet

Teva Pharmaceutical Industries Ltd (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Teva Pharmaceutical Industries Ltd (Teva) carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines in central nervous system (CNS), respiratory, cancer, women’s health and other therapy areas. The company offers generic medicines in a range of dosage forms, including capsules, tablets, injectables, liquids, inhalants, creams and ointments. Teva also provides over-the-counter (OTC) products, as well as active pharmaceutical ingredients (APIs), the essential raw materials to the drug manufacturing industry. It carries out OTC business principally through PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (P&G). The company conducts its worldwide operations through a network of global subsidiaries. Teva is headquartered in Petach Tikva, Israel.

Teva Pharmaceutical Industries Ltd (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion/divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics
Venture Financing
Auspex Pharma Raises US$20 Million In Series E Financing
Labrys Biologics Raises US$31 Million In Series A Financing
Auspex Pharma Raises US$25 Million In Series D Financing
Auspex Pharma Raises US$1.5 Million In Venture Financing
Gamida Cell Raises US$10 Million In Series E Financing
Teva Pharma Industries Invests In MultiGene Vascular Systems
SymBio Pharma Secures US$24.5 Million In Series E Financing Round
Partnerships
Teva Pharma Enters into Distribution Agreement with Celltrion
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab
Teva Pharma and Takeda Pharma Form Joint Venture
Teva Pharma Enters into Research Agreement with AbCellera Biologics
Egalet Enters into Agreement with Teva Pharma
Teva Pharma Partners with University College London and Imanova
Teva Pharma Enters into an Agreement with Microchips Biotech
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug
Abic Marketing Enters into Agreement with Arena Pharma
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs
Champions Enters Into Drug Discovery And Development Agreement With Teva
Teva Pharma Plans To Enter Into Partnerships
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test
Teva Pharma To Form Joint Venture With Handok Pharma
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax
Teva Pharma And Proctor & Gamble Finalize Joint Venture
Teva Pharma Forms Joint Venture With Procter & Gamble
Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa
Champions Biotech Enters Into An Agreement With Cephalon
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra
Celator Pharma Extends Research Agreement With Cephalon
Licensing Agreements
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics
Teva Pharma Enters into Licensing Agreement with Eagle Pharma for EP-3102
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo
Labrys Biologics Enters Into Licensing Agreement With Pfizer For RN-307
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig
Teva Animal Health Exercises Option For Licensing Agreement With Eden Research
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine
Lundbeck Enters Into Licensing Agreement With Cephalon
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI
ImmunGene Enters Into Licensing Agreement With Cephalon
Equity Offering
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares
American Well Raises USD10 Million in Private Placement of Shares
Ignyta Raises USD42 Million in Private Placement of Shares
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares
Auspex Pharma Completes IPO For US$96.6 Million
Debt Offering
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion
Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For US$875 Million
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million
Teva Pharma Completes Public Offering Of Notes Due 2021 For US$875 Million
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion
Teva Pharma Completes Public Offering Of 2.4% Senior Notes Due 2016 For US$950 Million
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$250 Million
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$500 Million
Asset Transactions
Teva Pharma May Sell Women’s Health Unit for USD2 Billion
OncBioMune Pharma to Acquire Norepinefrine in Mexico from Teva Pharma
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma
Teva Pharma May Divest its Assets
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma
Teva Pharma Plans to Divest Some Operations
Ignyta Acquires Four Oncology R&D Assets from Cephalon
ANI Pharma Acquires ANDA from Teva Pharma
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California
CleveXel Pharma Acquires Development Center From Teva Pharma
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma
Partners In Life Sciences Completes Acquisition Of Manufacturing Facility In Mitry-Mory From Cephalon
Acquisition
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma
Teva Pharma Acquires Anda from Allergan for USD500 Million
Teva Pharma, Mylan May Acquire Teut|Pfizer
Teva Pharma Acquires Rimsa for USD2.3 Billion
Teva Pharma to Acquire Gecko Health Innovations
Teva Pharma to Acquire 51% Stake in Immuneering
Teva Pharma Acquires Auspex Pharma
Ind-Swift Lab May Sell Stake in Company
Teva Pharma Completes Acquisition of Labrys Biologics
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer
Teva Pharma Completes Acquisition of MicroDose Therapeutx
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million
Teva Pharma Rumored To Acquire Amarin
Teva Completes Acquisition Of Cephalon For US$6,800 Million
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million
Teva Pharma Invests Additional US$19 Million In CureTech
Teva Pharma Industries Acquires Taiyo Pharma Industry
Cephalon Acquires 91.73% Stake In ChemGenex
Cephalon Acquires Gemin X Pharma
Clal Biotech Acquires Stake In TransPharma Medical From Teva
Cephalon Completes Acquisition Of 20% Stake In Mesoblast
Teva Pharma Industries Acquires Corporacion Infarmasa
Teva Pharma Industries Acquires THERAMEX From Merck Serono
Teva Pharmaceutical Industries Ltd - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Strategy And Business Planning
Mar 31, 2016: Takeda and Teva Establish “Teva Takeda Yakuhin” in Japan
Feb 24, 2016: Teva Pharmaceuticals Embarks on Strategic Corporate Identity Program to Build a Global Brand
Financial Announcements
May 11, 2017: Teva Reports First Quarter 2017 Financial Results
Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results
Jan 06, 2017: Teva Provides 2017 Financial Outlook
Nov 15, 2016: Teva Reports Third Quarter 2016 Results
Aug 04, 2016: Teva Reports Second Quarter 2016 Results
May 09, 2016: Teva Reports First Quarter 2016 Results
Feb 11, 2016: Teva Reports Full Year 2015 and Fourth Quarter Financial Results
Corporate Communications
Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer
Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman
Dec 05, 2016: Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson
Nov 08, 2016: Teva Announces Appointment of New Chief Legal Officer
Jan 25, 2016: Teva Releases Innovation and Social Responsibility Highlights
Legal and Regulatory
Dec 22, 2016: Teva Reaches Settlement with Government on FCPA
Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges
Aug 25, 2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated
Product News
10/12/2016: Teva Announces Launch of Generic Beyaz in the United States
06/08/2016: New drug to prevent migraine may start working in days
04/12/2016: Teva to Present Data on TEV-48125 at 68th AAN Annual Meeting
Clinical Trials
Jan 11, 2016: Active Biotech: Information regarding the clinical study LEGATO-HD
Jan 04, 2016: Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials
Other Significant Developments
Jul 15, 2016: PhRMA Welcomes Five New Member Companies
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Deals By Therapy Area, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics
Auspex Pharma Raises US$20 Million In Series E Financing
Labrys Biologics Raises US$31 Million In Series A Financing
Auspex Pharma Raises US$25 Million In Series D Financing
Auspex Pharma Raises US$1.5 Million In Venture Financing
Gamida Cell Raises US$10 Million In Series E Financing
Teva Pharma Industries Invests In MultiGene Vascular Systems
SymBio Pharma Secures US$24.5 Million In Series E Financing Round
Teva Pharma Enters into Distribution Agreement with Celltrion
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab
Teva Pharma and Takeda Pharma Form Joint Venture
Teva Pharma Enters into Research Agreement with AbCellera Biologics
Egalet Enters into Agreement with Teva Pharma
Teva Pharma Partners with University College London and Imanova
Teva Pharma Enters into an Agreement with Microchips Biotech
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug
Abic Marketing Enters into Agreement with Arena Pharma
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs
Champions Enters Into Drug Discovery And Development Agreement With Teva
Teva Pharma Plans To Enter Into Partnerships
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test
Teva Pharma To Form Joint Venture With Handok Pharma
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax
Teva Pharma And Proctor & Gamble Finalize Joint Venture
Teva Pharma Forms Joint Venture With Procter & Gamble
Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa
Champions Biotech Enters Into An Agreement With Cephalon
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra
Celator Pharma Extends Research Agreement With Cephalon
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics
Teva Pharma Enters into Licensing Agreement with Eagle Pharma for EP-3102
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo
Labrys Biologics Enters Into Licensing Agreement With Pfizer For RN-307
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig
Teva Animal Health Exercises Option For Licensing Agreement With Eden Research
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine
Lundbeck Enters Into Licensing Agreement With Cephalon
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI
ImmunGene Enters Into Licensing Agreement With Cephalon
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares
American Well Raises USD10 Million in Private Placement of Shares
Ignyta Raises USD42 Million in Private Placement of Shares
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares
Auspex Pharma Completes IPO For US$96.6 Million
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion
Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For US$875 Million
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million
Teva Pharma Completes Public Offering Of Notes Due 2021 For US$875 Million
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion
Teva Pharma Completes Public Offering Of 2.4% Senior Notes Due 2016 For US$950 Million
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$250 Million
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$500 Million
Teva Pharma May Sell Women’s Health Unit for USD2 Billion
OncBioMune Pharma to Acquire Norepinefrine in Mexico from Teva Pharma
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma
Teva Pharma May Divest its Assets
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma
Teva Pharma Plans to Divest Some Operations
Ignyta Acquires Four Oncology R&D Assets from Cephalon
ANI Pharma Acquires ANDA from Teva Pharma
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California
CleveXel Pharma Acquires Development Center From Teva Pharma
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma
Partners In Life Sciences Completes Acquisition Of Manufacturing Facility In Mitry-Mory From Cephalon
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma
Teva Pharma Acquires Anda from Allergan for USD500 Million
Teva Pharma, Mylan May Acquire Teut|Pfizer
Teva Pharma Acquires Rimsa for USD2.3 Billion
Teva Pharma to Acquire Gecko Health Innovations
Teva Pharma to Acquire 51% Stake in Immuneering
Teva Pharma Acquires Auspex Pharma
Ind-Swift Lab May Sell Stake in Company
Teva Pharma Completes Acquisition of Labrys Biologics
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer
Teva Pharma Completes Acquisition of MicroDose Therapeutx
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million
Teva Pharma Rumored To Acquire Amarin
Teva Completes Acquisition Of Cephalon For US$6,800 Million
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million
Teva Pharma Invests Additional US$19 Million In CureTech
Teva Pharma Industries Acquires Taiyo Pharma Industry
Cephalon Acquires 91.73% Stake In ChemGenex
Cephalon Acquires Gemin X Pharma
Clal Biotech Acquires Stake In TransPharma Medical From Teva
Cephalon Completes Acquisition Of 20% Stake In Mesoblast
Teva Pharma Industries Acquires Corporacion Infarmasa
Teva Pharma Industries Acquires THERAMEX From Merck Serono
Teva Pharmaceutical Industries Ltd, Key Competitors
Teva Pharmaceutical Industries Ltd, Key Employees
Teva Pharmaceutical Industries Ltd, Subsidiaries

LIST OF FIGURES

Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2011 to YTD 2017
Skip to top


Ask Your Question

Teva Pharmaceutical Industries Ltd (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: